Market Overview:
The global tyrosine kinase inhibitor market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing R&D expenditure by pharmaceutical companies, and growing demand for targeted therapies. Based on type, the global tyrosine kinase inhibitor market is segmented into phase-I, phase-I/II, phase-II, phase-II/III and phase-III. The Phase III segment is expected to account for the largest share of the global tyrosine kinase inhibitor market in 2018. This can be attributed to the high prevalence of cancer and increasing adoption of targeted therapies worldwide. Based on application, the global tyrosine kinase inhibitor market is segmented into breast cancer, glioblastoma and lung cancer other applications). The breast cancer segment accounted for the largest share ofthe global tyrosine kinase inhibitormarket in 2017andis projectedto grow at a CAGRof 11% duringthe forecast period.
Product Definition:
A tyrosine kinase inhibitor is a type of drug that blocks the action of tyrosine kinases. Tyrosine kinases are enzymes that play a role in the growth and spread of cancer cells. Blocking their action can help to stop or slow the growth of cancer cells.
Phase-I:
Phase-I is also known as 1st Line of Treatment or Early Phase Discovery. It's a term used for testing the drug in humans to see if it is safe for consumption by giving it to patients with higher than normal doses. This phase-I study involves giving the drug at a high dose and then studying its effects on people, which helps doctors decide on an appropriate dose for phase II testing.
Phase-I/II:
Phase-I/II is also known as pre-clinical or early phase clinical trial. It's an investigation of a new drug's safety and efficacy in humans, before the drug has been approved by the U.S. FDA (Food and Drug Administration). The purpose of this study is to determine whether the proposed drug has therapeutic potential for treating a particular disease state, prior to determining if it should be given approval for marketing or not.
Application Insights:
Breast cancer held the largest revenue share of over 25% in 2017. Tyrosine kinase inhibitors are widely used for the treatment of breast cancer, which is a major factor contributing to its large revenue share. The other application segment includes lung and other cancers. Currently, there are no effective drugs available for the treatment of non-small cell lung and other cancers; hence, these types of cancer therapies rely heavily on TKI drug combinations that have been developed after extensive R&D investments over several years.
The phase-I/II application segment dominated the global tyrosine kinase inhibitor market in terms of revenue generation in 2017 due to extensive product usage during this early stage as well as ongoing research regarding its potential use during this early stage along with ongoing clinical trials pertaining to different types of tumor entities including glioblastoma multiforme, Ewing¢â‚¬â„¢s tumor and renal carcinoma.
Regional Analysis:
North America dominated the global tyrosine kinase inhibitor market in 2017. This can be attributed to the presence of a large number of companies, availability of effective treatment methods, and high healthcare expenditure in this region. In addition, favorable government initiatives pertaining to drug development are also expected to drive growth during the forecast period. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing awareness about available treatments for cancer and their respective advantages as well as disadvantages along with rising disposable income levels in emerging countries such as China and India.
Major players operating in this industry include but are not limited too; AbbVie Inc.; AstraZeneca; Pfizer Inc.; Merck & Co., Inc.; Celgene Corporation; Biogen Inc.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the tyrosine kinase inhibitor market. According to the American Cancer Society, approximately 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and about 600,920 people will die from the disease. This number is expected to rise in future due to increase in aging population and lifestyle-related cancers such as obesity and smoking.
- Rising demand for targeted therapies: The rising demand for targeted therapies is another key growth driver for tyrosine kinase inhibitors market. Tyrosine kinases are a class of enzymes that play an important role in signal transduction pathways within cells that control cell division, differentiation, and survival signaling cascades initiated by various cytokines receptors on tumor cells make them attractive therapeutic targets . As a result, there is a growing demand for drugs that specifically target these enzymes thereby inhibiting tumor cell proliferation .
Scope Of The Report
Report Attributes
Report Details
Report Title
Tyrosine Kinase Inhibitor Market Research Report
By Type
Phase-I, Phase-I/II, Phase-II, Phase-II/III, Phase-III
By Application
Breast Cancer, Glioblastoma and Lung Cancer, Other
By Companies
Merck, Novartis, Pfizer, Sanofi, GalaxoSmithKline, Biogen Idec, Bayer Healthcare Pharmaceuticals, Johnson & Johnson, Tolero Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Tyrosine Kinase Inhibitor Market Report Segments:
The global Tyrosine Kinase Inhibitor market is segmented on the basis of:
Types
Phase-I, Phase-I/II, Phase-II, Phase-II/III, Phase-III
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Glioblastoma and Lung Cancer, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Novartis
- Pfizer
- Sanofi
- GalaxoSmithKline
- Biogen Idec
- Bayer Healthcare Pharmaceuticals
- Johnson & Johnson
- Tolero Pharmaceutical
Highlights of The Tyrosine Kinase Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Phase-I
- Phase-I/II
- Phase-II
- Phase-II/III
- Phase-III
- By Application:
- Breast Cancer
- Glioblastoma and Lung Cancer
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tyrosine Kinase Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A tyrosine kinase inhibitor is a type of medication that blocks the activity of tyrosine kinases. Tyrosine kinases are enzymes that play a role in the signaling pathway between cells. Blocking their activity can prevent cells from communicating and can lead to decreased cell growth and division.
Some of the major players in the tyrosine kinase inhibitor market are Merck, Novartis, Pfizer, Sanofi, GalaxoSmithKline, Biogen Idec, Bayer Healthcare Pharmaceuticals, Johnson & Johnson, Tolero Pharmaceutical.
The tyrosine kinase inhibitor market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tyrosine Kinase Inhibitor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tyrosine Kinase Inhibitor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tyrosine Kinase Inhibitor Market - Supply Chain
4.5. Global Tyrosine Kinase Inhibitor Market Forecast
4.5.1. Tyrosine Kinase Inhibitor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tyrosine Kinase Inhibitor Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tyrosine Kinase Inhibitor Market Absolute $ Opportunity
5. Global Tyrosine Kinase Inhibitor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Type
5.3.1. Phase-I
5.3.2. Phase-I/II
5.3.3. Phase-II
5.3.4. Phase-II/III
5.3.5. Phase-III
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tyrosine Kinase Inhibitor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Glioblastoma and Lung Cancer
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tyrosine Kinase Inhibitor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tyrosine Kinase Inhibitor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tyrosine Kinase Inhibitor Demand Share Forecast, 2019-2026
9. North America Tyrosine Kinase Inhibitor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Glioblastoma and Lung Cancer
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Type
9.7.1. Phase-I
9.7.2. Phase-I/II
9.7.3. Phase-II
9.7.4. Phase-II/III
9.7.5. Phase-III
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tyrosine Kinase Inhibitor Demand Share Forecast, 2019-2026
10. Latin America Tyrosine Kinase Inhibitor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Glioblastoma and Lung Cancer
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Type
10.7.1. Phase-I
10.7.2. Phase-I/II
10.7.3. Phase-II
10.7.4. Phase-II/III
10.7.5. Phase-III
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tyrosine Kinase Inhibitor Demand Share Forecast, 2019-2026
11. Europe Tyrosine Kinase Inhibitor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Glioblastoma and Lung Cancer
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Type
11.7.1. Phase-I
11.7.2. Phase-I/II
11.7.3. Phase-II
11.7.4. Phase-II/III
11.7.5. Phase-III
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tyrosine Kinase Inhibitor Demand Share, 2019-2026
12. Asia Pacific Tyrosine Kinase Inhibitor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Glioblastoma and Lung Cancer
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Type
12.7.1. Phase-I
12.7.2. Phase-I/II
12.7.3. Phase-II
12.7.4. Phase-II/III
12.7.5. Phase-III
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tyrosine Kinase Inhibitor Demand Share, 2019-2026
13. Middle East & Africa Tyrosine Kinase Inhibitor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Glioblastoma and Lung Cancer
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tyrosine Kinase Inhibitor Market Size and Volume Forecast by Type
13.7.1. Phase-I
13.7.2. Phase-I/II
13.7.3. Phase-II
13.7.4. Phase-II/III
13.7.5. Phase-III
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tyrosine Kinase Inhibitor Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tyrosine Kinase Inhibitor Market: Market Share Analysis
14.2. Tyrosine Kinase Inhibitor Distributors and Customers
14.3. Tyrosine Kinase Inhibitor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. GalaxoSmithKline
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biogen Idec
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bayer Healthcare Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Johnson & Johnson
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Tolero Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
